Biologic therapy for psoriasis: The new therapeutic frontier

Archives of Dermatology

Volumn 138, Issue 5, 2002, Pages 657-663

  Singri, Prashant ^a   West, Dennis P ^a   Gordon, Kenneth B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABX IL8; ALEFACEPT; CORTICOSTEROID; CYCLOSPORIN; DENILEUKIN DIFTITOX; EFALIZUMAB; EMBREL; ETANERCEPT; FONTOLIZUMAB; GALIXIMAB; GAMMA INTERFERON ANTIBODY; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; PSORALEN; RECOMBINANT DNA; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT PROTEIN; SIPLIZUMAB; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEVER; GENE THERAPY; HEADACHE; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ENGINEERING; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; TECHNOLOGY; ULTRAVIOLET A RADIATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; LYMPHOCYTE ACTIVATION; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0036578797     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Hematopoietic growth factors in cancer chemotherapy
2. Value of monoclonal antibody OKT3 in solid organ transplantation: A meta-analysis
3. Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity
4. New therapeutic targets for rheumatoid arthritis
5. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases
6. New cytokines and their clinical application
7. Safety of human recombinant proteins
8. Development of a recombinant growth factor and fusion protein: Lessons from GM-CSF
9. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis
10. Strategies for expressing human antibody repertoires in transgenic mice
11. Preparation of genetically engineered monoclonal antibodies for human immunotherapy
12. Alternative technologies to generate monoclonal antibodies
13. Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis
14. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
15. DAB4861L-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells
16. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
17. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
18. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects
19. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies
20. In vivo cell activation following OKT3 administration: Systemic cytokine release and modulation by corticosteroids
21. OKT3 first-dose reaction: Association with T cell subsets and cytokine release
22. The immunologic and genetic basis of psoriasis
23. Daclizumab: Outcome of phase III trials and mechanism of action: Double therapy and the triple therapy study groups
24. T cells involved in psoriasis vulgaris belong to the Th1 subset
25. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31)
26. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
27. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis
28. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes
29. Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis
30. +) is linked to serum levels of LFA3TIP
31. Reduction of the fraction of circulating helper-inducer T cells identified by monoclonal antibodies in psoriatic patients treated with long-term psoralen/ultraviolet-A radiation (PUVA)
32. + T lymphocytes
33. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles
34. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes
35. Immune deviation towards Th2 inhibits Th1-mediated autoimmune diabetes
36. Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease
37. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis
38. Cytokine system as potential target for antipsoriatic therapy
39. Interleukin-8 plays its role at local level in psoriasis vulgaris
40. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
41. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study
42. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma
43. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: Efficacy in mycosis fungoides and other non-Hodgkin's lymphomas
44. Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1124) in patients with psoriasis
45. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10: Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression
46. Results of a single-dose, dose-escalating trial of an anti-B7 monoclonal antibody (IDEC-114) in patients with psoriasis
47. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation: No 14874 and No 14393 Zenapax Study Groups
48. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
49. Phase I results of intravenous MEDI-507, an anti-T-cell monoclonal antibody, for the treatment of psoriasis
50. IL-11 is an immune-modulatory cytokine which down-regulates IL-12, type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis
51. Immune-mediated side-effects of cytokines in humans
52. IL-10 is a key cytokine in psoriasis: Proof of principle by IL-10 therapy: A new therapeutic approach
53. Interleukin 10 treatment of psoriasis: Clinical results of a phase II trial
54. Clinical and immunological effects of IL-10 therapy in psoriasis
55. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
56. Infliximab: A review of its use in the management of rheumatoid arthritis
57. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
58. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial